|
|
|
03/25/2024 08:30 |
Notice of the Settlement of Patent Infringement Litigation Related to Lenvatinib in the U.S. |
02/06/2024 12:30 |
FY 2023 (Ending March 31, 2024) Third Quarter Financial Results Reference Data |
02/06/2024 12:30 |
CONSOLIDATED FINANCIAL REPORT [IFRS] for the Nine-Month Period Ended December 31, 2023 |
11/07/2023 12:30 |
FY 2023 (Ending March 31, 2024) Second Quarter Financial Results Reference Data |
11/07/2023 12:30 |
CONSOLIDATED FINANCIAL REPORT [IFRS] for the Six-Month Period Ended September 30, 2023 |
10/04/2023 15:00 |
Notice of Absorption-Type Merger (Simplified Merger/Short-Form Merger) of KAN Research Institute, Inc. |
09/22/2023 19:45 |
Eisai and Merck Provide Update on Two Phase 3 Trials Evaluating LENVIMA Plus KEYTRUDA With Certain Types of Metastatic Non-Small Cell Lung Cancer |
08/02/2023 12:30 |
FY2023 (Ending March 31, 2024) First Quarter Financial Results Reference Data |
08/02/2023 12:30 |
CONSOLIDATED FINANCIAL REPORT [IFRS] for the Three-Month Period Ended June 30, 2023 |
06/29/2023 15:00 |
Position and Policy Regarding Reduction of the Investment Unit of the Company's Shares |
06/06/2023 08:45 |
Notification of Ransomware Incident |
05/26/2023 08:00 |
Notice of Convocation of the 111th Ordinary General Meeting of Shareholders |
05/15/2023 15:30 |
Notification Regarding the Disposal of Treasury Stock through Third-Party Allotment in Accordance with the Revision of the Stock Compensation System |
05/15/2023 15:30 |
Notification Regarding the Revision of the Compensation System for Directors and Corporate Officers and Stock Compensation System |
05/15/2023 12:30 |
FY2022 (Ended March 31, 2023) Full Year Financial Results Reference Data |
05/15/2023 12:30 |
CONSOLIDATED FINANCIAL REPORT [IFRS] for Fiscal 2022 (Year Ended March 31, 2023) |
05/09/2023 15:00 |
Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ended March 31, 2023 |
|